Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection

Table 1

Characteristics of study population.

	INF-free therapy; 54	INF-based therapy; 25
Age, median (range)	61 (40-78)	52 (25-70)
Sex male, (%)	43 (80%)	20 (80%)
Genotypes, (%)
1a	17 (31%)	8 (32%)
1b	22 (41%)	17 (68%)
Others	15 (28%)
FIB-4, median (range)	2.91 (0.9-11.84)	2.08 (0.5-20.44)
FibroScan (kPa), median (range)	22.7 (10.6-248)	11.6 (1.3-37.4)
HCV-RNA (10^6 cp/ml), median (range)	0.88(0.0014-3.12)	2.28 (0.78-7.95)
ALT (UI/l), median (range)	91 (28-407)	105 (42-288)
AST (UI/l), median (range)	69 (22-247)	73 (26-280)
PLT (10^9/l), median (range)	139 (28-340)	170 (34-290)
Cirrhotic, (%)	40 (70%)	9 (36%)
Fibrosis stage
F0-F2, (%)	1 (2%)	10 (40%)
F3, (%)	10 (19%)	6 (24%)
F4, (%)	41 (79%)	9 (36%)